You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Data in Context: 2021 Winter Updates in EBV-Positive Posttransplant Lymphoproliferative Disorder 

  • Authors: Corey S. Cutler, MD, MPH, FRCPC; Susan E. Prockop, MD­; Pierluigi Porcu, MD
  • CME / ABIM MOC Released: 2/24/2022
  • Valid for credit through: 2/24/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists and oncologists (including stem cell transplant specialists) and solid organ transplant surgeons. 

The goal of this activity is to improve the knowledge of hematologists and oncologists, hematopoietic stem cell transplantation (HSCT) specialists, and solid organ transplant (SOT) specialists about EBV-positive posttransplant lymphoproliferative disorder and emerging treatment approaches, including those presented at the 2021 winter hematology meeting, as well as the clinical context for new approaches.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Incidence of EBV-positive PTLD after SOT or HSCT
    • Frontline treatment options for EBV-positive PTLD 
    • Emerging approaches for treating rituximab-refractory, EBV-positive PTLD


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Corey S. Cutler, MD, MPH, FRCPC

    Associate Professor of Medicine
    Harvard Medical School
    Medical Director
    Adult Stem Cell Transplantation Program
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Disclosures

    Disclosure: Corey S. Cutler, MD, MPH, FRCPC, has the following relevant financial relationships:
    Advisor or consultant for: AlloVir; Bristol Myers Squibb; CareDx; Cimeio; Deciphera; Editas; ElsaLys; Fresenius-Kabi; Generon; Incyte; Janssen; Jazz; Kadmon (pro bono); Mallinckrodt; MEDSENIC; Mesoblast; Omeros; Pfizer; Sanofi; Syndax
    Other: DSMB: AlloVir

Panelist

  • Susan E. Prockop, MD

    Associate Director
    Clinical and Translational Research
    Stem Cell Transplantation Program
    Boston Children's Hospital
    Department of Pediatric Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Disclosures

    Disclosure: Susan Prockop, MD, has the following relevant financial relationships:
    Advisor or consultant for: Neovii; ADMA
    Grants for clinical research from: Atara Biotherapeutics; AlloVir; Jasper Therapeutics
    Other: Inventor of intellectual property related to third-party viral-specific T cells, with all rights assigned to Memorial Sloan Kettering Cancer Center (former employer).

  • Pierluigi Porcu, MD

    Director
    Professor of Medical Oncology, Dermatology, and Cutaneous Biology
    Director, Division of Hematologic Malignancies and
    Hematopoietic Stem Cell Transplantation
    Sidney Kimmel Cancer Center
    Thomas Jefferson University
    Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Pierluigi Porcu, MD, has disclosed the following relevant financial relationships:
    Advisor or consultant for: Daiichi Sankyo; Innate Pharma; Kyowa Kirin; Viracta
    Grants for clinical research from: Daiichi Sankyo; Innate Pharma; Kyowa Kirin; Viracta

Editor

  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Heather P. Friedman, MPH, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Data in Context: 2021 Winter Updates in EBV-Positive Posttransplant Lymphoproliferative Disorder 

Authors: Corey S. Cutler, MD, MPH, FRCPC; Susan E. Prockop, MD­; Pierluigi Porcu, MDFaculty and Disclosures

CME / ABIM MOC Released: 2/24/2022

Valid for credit through: 2/24/2023

processing....

Pre-Assessment Survey

Before you begin, please take this brief survey.

  • Print